Skip to main content
OpenTrials
Completed

NCT Number: NCT03946813

The Efficacy of Platelets Rich Plasma for Ovarian Rejuvenation

In recent years, an increased approach has appeared in the use of autologous blood products to assist tissue and organ healing. Application of platelet rich plasma (PRP) has emerged as a potential solution for infertile women with poor ovarian reserve in reproductive specialty.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infertility Urogenital Diseases

Age range

20 year–49 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

High Institute for Infertility Diagnosis and Assisted Reproductive Technologies

Baghdad, Iraq

About this study

Quantitative and qualitative functional improvement of ovarian function has been reported in several studies after using autologous PRP in a reproductive field. Ovarian rejuvenation, stimulating the ovaries to produce new eggs after injecting PRP, can offer hope for renewed fertility to women with poor reserve volume, advanced maternal age, or either naturally occurring or premature menopause. But, these encouraging results should be supported by several new studies.

This study aimed to estimate the efficacy of trans-vaginal ovarian injection with PRP in rejuvenates ovaries in woman with poor ovarian reserve, and to assess any association of some women variables (age, menstrual status, parity, BMI) as predicting factors in success of ovarian injection with PRP.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Menopause or peri-menopause under the age of 50.
  • Premature ovarian insufficiency which is ovarian failure before the age of 40.
  • Woman with primary ovarian failure of any cause.

Exclusion criteria

  • A previous injection with any medication, plasma, or PRP
  • Invisible or difficult access ovaries.
  • Medical disease or unfit for anesthesia patient.

Treatment and study plan

Autologous PRP preparation

Other

For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide

Other names: Plasma Rich Platelets

Primary outcomes

  1. Follicle-stimulating hormone (FSH) concentration

    Time frame: 4 weeks

    Before after intervention measurement

  2. Anti-Müllerian hormone (AMH) concentration

    Time frame: 4 weeks

    Before after intervention measurement

  3. Antral follicles numbers

    Time frame: 4 weeks

    Before after intervention measurement

Sponsors and collaborators

Lead sponsor

Al-Kindy College of Medicine

Other

Collaborators

  • High Institute for Infertility Diagnosis and Assisted Reproductive Technologies

Registry information

Official study title

The Efficacy of Platelets Rich Plasma (PRP) for Ovarian Rejuvenation

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
May 13, 2019
Registry last updated
May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.